A recent article in the Long Island Business News has reported on the new Bioscience Technology Commercialization Fund from Stony Brook University. This fund has allocated grants from $25,000 to $100,000 to projects involving musculoskeletal diseases, metabolic and cognitive disorders, cancer, burn injuries, inflammatory diseases and other medical conditions.
The money is meant to be “a catalyst to ensuring that groundbreaking biomedical research taking place at Stony Brook University advances with the ultimate goal to reach patients with better diagnostics and therapeutics.”
A recipient of one of these grants is Clint Rubin, Chief Scientific Officer of Marodyne Medical, in order to research into developing low intensity vibrations or LIV therapy.
Marodyne Medical already is developing the technology to treat osteoporosis, according to the school. Rubin’s research into “LIV therapy” focuses on using it to treat diabetes, bone marrow disorders and cognitive dysfunction. Low intensity vibrations cause small, muscle contractions that can strengthen muscles and bones, according to the school.